Extract
Breathlessness is the most common and disabling symptom in patients with interstitial lung disease (ILD), significantly affecting their quality of life. Therefore, alleviating breathlessness is a primary focus in the symptom management of patients with ILD. However, therapeutic options for patients with ILD are limited [1]. Herein, we introduce a novel symptom-based treatment for breathlessness in patients with ILD.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: None
- Received December 20, 2022.
- Accepted April 20, 2023.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org